| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.80 M USD | -6.98 M USD | -8.45 M USD | -9.30 M USD | -12.09 M USD | -6.13 M USD | -4.95 M USD | -2.10 M USD | — |
| Depreciation & Amortization | — | — | — | — | — | 1043 USD | 1225 USD | 1224 USD | — |
| Stock-Based Compensation | 1.19 M USD | 804277 USD | 216428 USD | 620798 USD | 1.32 M USD | 737746 USD | 2.50 M USD | 143053 USD | — |
| Capital Expenditures | — | — | — | — | — | — | — | — | — |
| Cash Flow from Investing | -300000 USD | — | — | 1.16 M USD | -165355 USD | -1.84 M USD | -895000 USD | — | — |
| Cash Flow from Financing | 9.31 M USD | 4.74 M USD | 11.32 M USD | 6.04 M USD | 18.19 M USD | 8.73 M USD | 7.45 M USD | 1.15 M USD | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -9.80 M USD | — | — | — | — | — | — | — | — |
Rocket One Inc. is a technology company focused on developing and commercializing infrastructure for the orbital economy and advanced computing markets. Headquartered in Hoboken, New Jersey, the company centers its activities on next-generation nanomagnetic AI chip architectures designed for ultra-low-power, radiation-tolerant computing in space and defense environments. These chips target use cases such as low-Earth orbit satellites, deep-space platforms, and mission-critical defense systems where reliability, energy efficiency, and resilience to radiation are essential. Rocket One holds exclusive rights to nanomagnetic matrix-multiplier hardware accelerators for machine learning and AI workloads, along with related magnetic memory technologies aimed at radiation-tolerant computing. In addition, the company is positioned to pursue opportunities in nano-launch systems and nanosatellite deployment, linking its semiconductor capabilities with broader space-infrastructure applications. Rocket One also maintains a biotechnology pipeline, including programs in oncology side-effect management, mast-cell cancers, neuroinflammatory diseases, dermatology, respiratory conditions, and metabolic disorders, which are advanced through a wholly owned subsidiary. This combination of space-focused AI hardware and specialized biotech assets gives Rocket One a distinct multi-sector presence in today’s public markets.